Goldman Sachs' ratings triggered price movements, with Syngene and Neuland rising but Laurus falling. Syngene is set to benefit from China+1, while Neuland sees growth opportunities in APIs and chemistry solutions. In contrast, Laurus faces challenges in its business transition and growth prospects.